Colon to Rectum
J Clin Oncol. 2022;40(15):1681–92
Multicenter, randomized, phase 3 trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)
Purpose: To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy (CRT) in patients with locally advanced rectal cancer.
Materials and methods: Patients with distal or middle-third, clinical primary tumor stage 3–4 and/or regional lymph node-positive rectal cancer were randomly assigned (1:1) to short-term radiotherapy (25 Gy in 5 fractions over 1 week) followed by 4 cycles of chemotherapy (total neoadjuvant therapy [TNT]) or CRT (50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine [CRT]). Total mesorectal excision was undertaken 6–8 weeks after preoperative treatment, with 2 additional cycles of CAPOX (intravenous oxaliplatin [130 mg/m², once daily] on day 1 and capecitabine [1000 mg/m², twice daily] from days 1–14) in the TNT group and 6 cycles of CAPOX in the CRT group. The primary end point was 3-year disease-free survival (DFS).
Results: Between August 2015 and August 2018, a total of 599 patients were randomly assigned to receive TNT (n = 302) or CRT (n = 297). At a median follow-up of 35 months, 3-year DFS was 64.5% and 62.3% in TNT and CRT groups, respectively (hazard ratio = 0.883, 1-sided 95% confidence interval, not applicable to 1.11; pnon-inferiority < 0.001). There was no significant difference in metastasis-free survival or locoregional recurrence, but the TNT group had better 3-year overall survival than the CRT group (86.5% vs. 75.1%; p = 0.033). Treatment effects on DFS and overall survival were similar regardless of prognostic factors. The prevalence of acute grade III–V toxicities during preoperative treatment was 26.5% in the TNT group versus 12.6% in the CRT group (p < 0.001).
Conclusion: Short-term radiotherapy with preoperative chemotherapy followed by surgery was efficacious with acceptable toxicity and could be used as an alternative to chemoradiotherapy for locally advanced rectal cancer.
DOI: 10.1200/jco.21.01667